GDC-2394
GDC-2394 is an orally active and selective NLRP3 inhibitor, and also inhibits IL-1β with IC50s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β) . GDC-2394 inhibits NLRP3-induced caspase-1 activity without inhibiting NLRC4-dependent inflammasome activation[1][2].
Product Specifications
CAS Number
2238822-07-4
UNSPSC
12352005
Target
Caspase; Interleukin Related; NOD-like Receptor (NLR)
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/gdc-2394.html
Purity
99.87
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=S(C1=C2OC[C@@H](NC)CN2N=C1)(NC(NC3=C4CCCC4=CC5=C3CCC5)=O)=O
Molecular Formula
C20H25N5O4S
Molecular Weight
431.51
References & Citations
[1]McBride C, et al. Overcoming Preclinical Safety Obstacles to Discover (S) -N- ((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl) carbamoyl) -6- (methylamino) -6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394) : A Potent and Selective NLRP3 Inhibitor. J Med Chem. 2022 Oct 24. |[2]Stafford, et al. Preparation of hexahydroindacenylcarbamoyldihydropyrazolooxazinesulfonamide derivatives and analogs for use as interleukin-1 activity inhibitors: World Intellectual Property Organization, WO2018136890[P]. 2018-07-26.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
